T
Thiago Trovati Maciel
Researcher at Paris Descartes University
Publications - 39
Citations - 2062
Thiago Trovati Maciel is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 16, co-authored 29 publications receiving 1639 citations. Previous affiliations of Thiago Trovati Maciel include Collège de France & Paris Diderot University.
Papers
More filters
Journal ArticleDOI
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Nathalie Jacque,Anne Marie Ronchetti,Clément Larrue,Clément Larrue,Godelieve Meunier,Rudy Birsen,Lise Willems,Estelle Saland,Estelle Saland,Justine Decroocq,Thiago Trovati Maciel,Mireille Lambert,Laury Poulain,Pierre Sujobert,Laure Joseph,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Ivan C. Moura,Susan Demo,Jean-Emmanuel Sarry,Jean-Emmanuel Sarry,Christian Recher,Christian Recher,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Didier Bouscary +28 more
TL;DR: It is shown that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells and targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.
Journal ArticleDOI
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia
Michael Dussiot,Thiago Trovati Maciel,Aurélie Fricot,Céline Chartier,Olivier Negre,Joel Veiga,Damien Grapton,Etienne Paubelle,Emmanuel Payen,Yves Beuzard,Philippe Leboulch,Jean-Antoine Ribeil,Jean-Benoît Arlet,Francine Côté,Geneviève Courtois,Yelena Ginzburg,Thomas O. Daniel,Rajesh Chopra,Victoria Sung,Olivier Hermine,Ivan C. Moura +20 more
TL;DR: Observations suggest that ActRIIA ligand traps may have therapeutic relevance in β-thalassemia by suppressing the deleterious effects of GDF11, a cytokine which blocks terminal erythroid maturation through an autocrine amplification loop involving oxidative stress and α-globin precipitation.
Journal ArticleDOI
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Lise Willems,Lise Willems,Nathalie Jacque,Arnaud Jacquel,Nathalie Neveux,Thiago Trovati Maciel,Mireille Lambert,Alain Schmitt,Laury Poulain,Alexa S. Green,Madalina Uzunov,Olivier Kosmider,Olivier Kosmider,Isabelle Radford-Weiss,Ivan C. Moura,Patrick Auberger,Norbert Ifrah,Valérie Bardet,Valérie Bardet,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Jerome Tamburini,Didier Bouscary,Didier Bouscary +28 more
TL;DR: It is shown that glutamine removal inhibits mTORC1 and induces apoptosis in AML cells, and that l-ases upregulate glutamine synthase expression in leukemic cells and that a GS knockdown enhances l-ase-induced apoptotic response in someAML cells.
Journal ArticleDOI
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Alexa S. Green,Alexa S. Green,Nicolas Chapuis,Nicolas Chapuis,Thiago Trovati Maciel,Lise Willems,Lise Willems,Mireille Lambert,Mireille Lambert,Christophe Arnoult,Olivier Boyer,Valérie Bardet,Valérie Bardet,Sophie Park,Marc Foretz,Marc Foretz,Benoit Viollet,Benoit Viollet,Norbert Ifrah,François Dreyfus,Olivier Hermine,Ivan C. Moura,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Didier Bouscary,Jerome Tamburini +27 more
TL;DR: The induction of the LKB1/AMPK/TSC tumor suppressor axis is functional in AML and can be activated by the biguanide molecule metformin, resulting in a specific inhibition of mammalian target of rapamycin catalytic activity.
Journal ArticleDOI
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Lise Willems,Nicolas Chapuis,Nicolas Chapuis,Alexandre Puissant,Thiago Trovati Maciel,Alexa S. Green,Alexa S. Green,Nathalie Jacque,Nathalie Jacque,Christine Vignon,Sophie Park,Sophie Park,Sylvie Guichard,Olivier Herault,Aurélie Fricot,Olivier Hermine,Ivan C. Moura,Patrick Auberger,Norbert Ifrah,Francois Dreyfus,Dominique Bonnet,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Didier Bouscary,Jerome Tamburini,Jerome Tamburini +27 more
TL;DR: AZD8055 decreased AML blast cell proliferation and cell cycle progression, reduced the clonogenic growth of leukemic progenitors and induced caspase-dependent apoptosis inLeukemic cells but not in normal immature CD34+ cells, and induced autophagy, which may be either protective or cell death inducing, depending on concentration.